Literature DB >> 18245482

Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.

Nupur Gupta1, Jeffrey Delrow, Amar Drawid, Anirvan M Sengupta, Gaofeng Fan, Céline Gélinas.   

Abstract

Persistent Rel/nuclear factor-kappaB (NF-kappaB) activity is a hallmark of many human cancers, and the Rel proteins are implicated in leukemia/lymphomagenesis but the mechanism is not fully understood. Microarray analysis to identify transformation-impacting genes regulated by NF-kappaB's oncogenic v-Rel and c-Rel proteins uncovered that Rel protein expression leads to transcriptional repression of key B-cell receptor (BCR) components and signaling molecules like B-cell linker (BLNK), the B-cell adaptor for phosphoinositide 3-kinase (BCAP) and immunoglobulin lambda light chain (Ig lambda), and is accompanied by a block in BCR-mediated activation of extracellular signal-regulated kinase, Akt, and c-Jun-NH(2)-kinase in response to anti-IgM. The BLNK and BCAP proteins were also down-regulated in lymphoid cells expressing a transformation-competent chimeric RelA/v-Rel protein, suggesting a correlation with the capacity of Rel proteins to transform lymphocytes. DNA-binding studies identified functional NF-kappaB-binding sites, and chromatin immunoprecipitation (ChIP) data showed binding of Rel to the endogenous blnk and bcap promoters in vivo. Importantly, restoration of either BLNK or BCAP expression strongly inhibited transformation of primary chicken lymphocytes by the potent NF-kappaB oncoprotein v-Rel. These findings are interesting because blnk and other BCR components and signaling molecules are down-regulated in primary mediastinal large B-cell lymphomas and Hodgkin's lymphomas, which depend on c-Rel for survival, and are consistent with the tumor suppressor function of BLNK. Overall, our results indicate that down-regulation of BLNK and BCAP is an important contributing factor to the malignant transformation of lymphocytes by Rel and suggest that gene repression may be as important as transcriptional activation for Rel's transforming activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245482      PMCID: PMC2267479          DOI: 10.1158/0008-5472.CAN-07-3169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  c-Rel is required for the protection of B cells from antigen receptor-mediated, but not Fas-mediated, apoptosis.

Authors:  A M Owyang; J R Tumang; B R Schram; C Y Hsia; T W Behrens; T L Rothstein; H C Liou
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

2.  BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation.

Authors:  T Okada; A Maeda; A Iwamatsu; K Gotoh; T Kurosaki
Journal:  Immunity       Date:  2000-12       Impact factor: 31.745

3.  The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes.

Authors:  J E Tan; S C Wong; S K Gan; S Xu; K P Lam
Journal:  J Biol Chem       Date:  2001-03-23       Impact factor: 5.157

4.  Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius.

Authors:  P E Neiman; A Ruddell; C Jasoni; G Loring; S J Thomas; K A Brandvold; J Burnside; J Delrow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

5.  The absence of SLP65 and Btk blocks B cell development at the preB cell receptor-positive stage.

Authors:  H Jumaa; M Mitterer; M Reth; P J Nielsen
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

6.  RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.

Authors:  H Y Jiang; Constantinos Petrovas; Gail E Sonenshein
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

Authors:  U Kordes; D Krappmann; V Heissmeyer; W D Ludwig; C Scheidereit
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

8.  Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts.

Authors:  R Hrdlicková; J Nehyba; H R Bose
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.

Authors:  T D Gilmore; C Cormier; J Jean-Jacques; M E Gapuzan
Journal:  Oncogene       Date:  2001-10-25       Impact factor: 9.867

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  13 in total

1.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

2.  [Structure and function of B-cell linker and its role in the development of B cell-related diseases].

Authors:  Bin Xiao; Jiaying Li; Mengsi Zhou; Xiaoqing Li; Xiaoyan Huang; Jianfeng Hang; Zhaohui Sun; Linhai Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

3.  NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.

Authors:  Ryan C Thompson; Melanie Herscovitch; Ian Zhao; Tyler J Ford; Thomas D Gilmore
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

4.  TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.

Authors:  Eleni Kotsiou; Jessica Okosun; Caroline Besley; Sameena Iqbal; Janet Matthews; Jude Fitzgibbon; John G Gribben; Jeffrey K Davies
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

5.  Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.

Authors:  M Chin; M Herscovitch; N Zhang; D J Waxman; T D Gilmore
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

6.  Re-annotation is an essential step in systems biology modeling of functional genomics data.

Authors:  Bart H J van den Berg; Fiona M McCarthy; Susan J Lamont; Shane C Burgess
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

7.  Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family.

Authors:  Gaofeng Fan; Yongjun Fan; Nupur Gupta; Isao Matsuura; Fang Liu; Xiao Zhen Zhou; Kun Ping Lu; Céline Gélinas
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

8.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.

Authors:  Alyssa Bouska; Timothy W McKeithan; Karen E Deffenbacher; Cynthia Lachel; George W Wright; Javeed Iqbal; Lynette M Smith; Weiwei Zhang; Can Kucuk; Andrea Rinaldi; Francesco Bertoni; Jude Fitzgibbon; Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Bhavana J Dave; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Jan Delabie; Elaine S Jaffe; Rita M Braziel; Joseph M Connors; Louis M Staudt; Wing-Chung Chan
Journal:  Blood       Date:  2013-09-13       Impact factor: 22.113

9.  ERK and JNK activation is essential for oncogenic transformation by v-Rel.

Authors:  J Kralova; J I Sheely; A S Liss; H R Bose
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

10.  OHMM: a Hidden Markov Model accurately predicting the occupancy of a transcription factor with a self-overlapping binding motif.

Authors:  Amar Drawid; Nupur Gupta; Vijayalakshmi H Nagaraj; Céline Gélinas; Anirvan M Sengupta
Journal:  BMC Bioinformatics       Date:  2009-07-07       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.